Taiho and Cullinan's Zipalertinib Shows Early Success in Phase 3 Trial for First-Line Lung Cancer Treatment
REZILIENT3: Interim Analysis Meets Primary Endpoint
Taiho Pharmaceutical and Cullinan Therapeutics (CGEM) announced that the zipalertinib (CLN-081/TAS6417) combination arm in the global Phase 3 REZILIENT3 trial met its primary endpoint of progression-free survival (PFS). The Independent Data Monitoring Committee (IDMC) recommended unblinding the trial after the pre-planned interim analysis, confirming statistically significant and clinically meaningful improvements. This indicates that the pre-defined efficacy criteria have been surpassed, and the overall survival (OS) and detailed safety data will be crucial in assessing its competitive edge in subsequent academic presentations.
Oral EGFR Inhibitor Challenges First-Line Treatment Standard
Zipalertinib is an orally administered, small-molecule tyrosine kinase inhibitor (TKI) designed to irreversibly inhibit EGFR with exon 20 insertion mutations while relatively preserving normal EGFR. REZILIENT3 enrolled 285 patients with previously untreated, locally advanced, or metastatic non-squamous non-small cell lung cancer and compared zipalertinib in combination with pemetrexed and platinum-based chemotherapy to chemotherapy alone. Johnson & Johnson's (JNJ) Rybrevant (amivantamab-vmjw), an EGFR/MET bispecific antibody, received FDA approval on March 1, 2024, and is currently the standard of care in the U.S. Therefore, zipalertinib must differentiate itself through oral administration convenience and safety.
Second-Line Approval and Market Competition Proceed Simultaneously
The FDA accepted the New Drug Application (NDA) for zipalertinib on April 2026, targeting patients who have progressed after platinum-based chemotherapy, with a Prescription Drug User Fee Act (PDUFA) decision date of February 27, 2027. In this indication, it directly competes with Dizal Pharmaceutical's (688192) Zegfrovy (sunvozertinib), a mutant-selective EGFR TKI, which received accelerated approval on July 2, 2025, and Rybrevant as a single agent. Arivent BioPharma's (AVBP) irreversible pan-EGFR TKI, pimozertinib, is also competing in the Phase 3 FURVENT trial for first-line treatment, meaning that efficacy, as well as rash, diarrhea, hematological toxicity, and central nervous system activity, will determine market share.
$2.8 Billion Market and Profit-Sharing Structure
The market for EGFR exon 20 insertion inhibitors is projected to grow from $616 million in 2025 to $2.841 billion in 2034, with a compound annual growth rate of 18.5%. Taiho acquired Cullinan Pearl in 2022 for an upfront payment of $275 million, and Cullinan retains up to $130 million in regulatory milestone payments and a 50% share of U.S. development costs and pre-tax profits. Therefore, the success of the Phase 3 trial not only increases the clinical value but also enhances Cullinan's potential for milestone payments and long-term profit sharing in the U.S., strengthening Taiho's commercial assets in lung cancer as part of the Otsuka Holdings (4578) group.
The early PFS success in the Phase 3 REZILIENT3 trial, involving 285 patients, positions zipalertinib as a promising competitor in the Phase 3 stage for first-line treatment and provides consistent efficacy data for the second-line NDA, which has a FDA decision date of February 27, 2027. In the short term, Cullinan Therapeutics (CGEM) may see a reevaluation of its potential for up to $130 million in regulatory milestone payments and a 50% share of U.S. pre-tax profits. In the medium to long term, in the $2.841 billion market of 2034, Rybrevant, chemotherapy, Zegfrovy, and the Phase 3 pimozertinib will compete directly based on efficacy, safety, and ease of administration. From an R&D perspective, detailed PFS, OS, and brain metastasis data, as well as data on rash, diarrhea, and hematological toxicity, will determine whether it is a best-in-class drug.
Source: BioPharma Dive (rss)